Researchers studied a specific type of radiation therapy called fractionated stereotactic radiation therapy (FSRT) for patients with breast cancer who had between one and ten lesions in their brains. The study included 173 patients treated at a single institution. The goal was to see how well the treatment kept the cancer in the brain under control and how long patients lived.
After a median follow-up of 15 months, the treatment showed a one-year local control rate of 88.6%. This means the cancer stayed controlled at the treated site in most patients. The study also found that median overall survival was 29 months, and the therapy was generally well-tolerated with no severe radiation-related side effects observed.
Safety data showed that 6.2% of treated lesions experienced radiation necrosis, a known risk of radiation therapy. Because this was a single-arm trial, there was no control group to compare against. Readers should understand that these findings are preliminary and need confirmation in larger, randomized trials before changing standard care.
The main takeaway is that this approach appears effective for this specific group, but it does not prove it is better than other options. More research is needed to fully understand long-term outcomes and how this treatment compares to existing therapies.
